A Phase 3 Randomized Double-Blind Placebo-Controlled Parallel Arm Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease

Recruiting

99 years and younger

All

1 Location

Brief description of study

PROOF-HD is a placebo-controlled (double blind) multicenter Phase 3 trial of Pridopidine in Huntington Disease patients. Recruitment: 480 participants at 60 sites, a target of 8 participants per site. Procedures include administration of study drug or placebo in tablet form twice daily for a period of 67-80 weeks with option for OLE. Participation requires periodic on-site visits as well as virtual and phone visits. EKG and lab monitoring, physical exam and motor testing, interview tools.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

Updated on 11 Aug 2021. Study ID: 844637

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).